1,5,2,4-dioxadithiocane-2,2,4,4-tetraoxide (compound II) and 1,5,2,4-dioxadithionane-2,2,4,4-tetraoxide (compound III) are two structural analogues of the anticancer agent cyclodisone. Compound III was found to be more toxic to human colon carcinoma cells of the Mer- phenotype (BE) than the Mer+ phenotype (HT-29). In contrast, compound II showed little preferential toxicity with both cell lines being equally sensitive to this agent. DNA interstrand crosslinks were induced in the sensitive cell line by compound III but only at concentrations which were extremely cytotoxic. No DNA interstrand crosslinks were detected in the resistant cell line by compound III nor in either cell line by compound II. Total crosslinks which reflects both DNA interstrand and DNA-protein crosslinks, were observed in both cell lines after exposure to each agent although the kinetics of formation and repair of these lesions differed between both the compounds and each cell line. DNA strand breaks were also induced in both cell lines by each compound and were found to be totally 'protein associated' with compound III and to a lesser extend with compound II. The mechanism of action of this class of compound is thus different from other bifunctional alkylating agents and has still to be identified.

01 Jan 1989·Cancer Chemotherapy and PharmacologyQ4 · MEDICINE

Inhibition of cellular esterases by the antitumour imidazotetrazines mitozolomide and temozolomide: demonstration by flow cytometry and conventional spectrofluorimetry

Q4 · MEDICINE

Article

Author: C. Dive ; P. Workman ; J. V. Watson

Using flow cytometry and conventional spectrofluorimetry we have previously shown that chloroethylnitrosoureas (CNUs) can exhibit marked inhibition of cellular enzymes catalysing hydrolysis of fluorescein diacetate (FDA). More potent inhibition was seen for the carbamoylating CNUs, whereas alkylating agents were largely inactive. We now report results obtained with the developmental imidazotetrazines mitozolomide and temozolomide in comparison with BCNU, the novel alkylating agents clomesome and cyclodisone, and the active mitozolomide metabonate MCTIC. Inhibition of EMT6 mouse mammary-tumour esterases was seen for mitozolomide and temozolomide, and activity against purified porcine carboxylesterase was demonstrated. Flow cytometric analysis showed that inhibition occurred across the entire EMT6 cell population, with no evidence of a subpopulation resistant to enzyme inhibition. Inhibitory potency for the imidazotetrazines was much weaker than for BCNU. With EMT6 cells, I50 values from flow cytometry were 9.7 x 10(-3) M and 1.5 x 10(-3) M for mitozolomide and temozolomide compared with 3.7 x 10(-4) M for BCNU. These were higher than the ID50 values for in vitro antitumour activity (MTT assay), 8.5 x 10(-6) M in the case of mitozolomide and 1.2 x 10(-5) M for BCNU, but similar to that of 5.6 x 10(-4) M for the less toxic temozolomide. MCTIC and cyclodisone showed very low activity, but significant inhibition was seen for clomesome. The results are consistent with the view that the imidazotetrazines do not exhibit major carbamoylating ability, although significant effects are seen at cytotoxic concentrations of temozolomide. In addition, the potential for the generation of carbamoylating species at the enzyme active site cannot be ruled out.

01 Jan 1989·Cancer research

Characterization of DNA damage and cytotoxicity induced in two human colon carcinoma cell lines by cyclodisone.

Article

Author: Gibson, N W

Cyclodisone is an active alkylating antitumor agent that is being considered for Phase 1 clinical trials in humans and is currently undergoing toxicological evaluation. Cyclodisone was found to be more toxic to human colon carcinoma cells of the Mer- phenotype (BE) than cells of the Mer+ phenotype (HT-29). DNA interstrand cross-links were observed in the sensitive cell line but only at concentrations which were extremely toxic. No DNA interstrand cross-links were observed in the resistant cell line. Total DNA cross-links, which reflect both DNA interstrand and DNA-protein cross-linking, were observed in either cell type but were greater in quantity and persisted longer in the sensitive BE cell line, when compared to those produced in the resistant HT-29 cell line. DNA strand breaks were also observed in both cell types and were found to be protein associated. The mechanism of action of cyclodisone would appear to be related to the presence of total DNA cross-links and might involve an, as yet, unidentified DNA-protein interaction.

100 Deals associated with Cyclodisone

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Phase 3	US	National Institutes of Health	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Cyclodisone

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation